SH
BDTX icon

SLT Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

SLT Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,000
Closed -$66.3K – 93
2024
Q4 		$66.3K Buy
+31,000
New +$88.8K 0.06% 87

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SLT Holdings's BDTX Position: Q1 2025 in Review

SLT Holdings sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 31,000 shares — an estimated $66.3K sold.

SLT Holdings first reported a position in BDTX in Q4 2024 and held it in 1 quarter. The position peaked at $66.3K in Q4 2024. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • SLT Holdings reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SLT Holdings sold 31,000 Black Diamond Therapeutics shares in Q1 2025, an estimated $66.3K.
  • SLT Holdings first reported a position in Black Diamond Therapeutics in Q4 2024 and held it in 1 quarter.
  • SLT Holdings's Black Diamond Therapeutics position peaked at $66.3K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on SLT Holdings's 13F filing for Q1 2025, filed 7 May 2025.